Stock Analysis

Aethlon Medical Third Quarter 2023 Earnings: US$0.12 loss per share (vs US$0.16 loss in 3Q 2022)

Advertisement

Aethlon Medical (NASDAQ:AEMD) Third Quarter 2023 Results

Key Financial Results

  • Net loss: US$2.85m (loss widened by 13% from 3Q 2022).
  • US$0.12 loss per share.
earnings-and-revenue-growth
NasdaqCM:AEMD Earnings and Revenue Growth February 15th 2023

All figures shown in the chart above are for the trailing 12 month (TTM) period

Aethlon Medical Earnings Insights

Looking ahead, revenue is expected to decline by 124% p.a. on average during the next 3 years, while revenues in the Medical Equipment industry in the US are expected to grow by 7.5%.

Performance of the American Medical Equipment industry.

The company's shares are down 14% from a week ago.

Risk Analysis

It's necessary to consider the ever-present spectre of investment risk. We've identified 6 warning signs with Aethlon Medical (at least 3 which are concerning), and understanding these should be part of your investment process.

New: Manage All Your Stock Portfolios in One Place

We've created the ultimate portfolio companion for stock investors, and it's free.

• Connect an unlimited number of Portfolios and see your total in one currency
• Be alerted to new Warning Signs or Risks via email or mobile
• Track the Fair Value of your stocks

Try a Demo Portfolio for Free

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

About NasdaqCM:AEMD

Aethlon Medical

A medical therapeutic company, engages in developing novel immunotherapeutic devices to treat cancer and viral infections in the United States.

Medium-low risk with mediocre balance sheet.

Advertisement

Weekly Picks

RO
RockeTeller
SCZ logo
RockeTeller on Santacruz Silver Mining ·

Crazy Undervalued 42 Baggers Silver Play (Active & Running Mine)

Fair Value:CA$8696.7% undervalued
50 users have followed this narrative
6 users have commented on this narrative
16 users have liked this narrative
RO
Robbo
FID logo
Robbo on Fiducian Group ·

Fiducian: Compliance Clouds or Value Opportunity?

Fair Value:AU$122.0% undervalued
7 users have followed this narrative
0 users have commented on this narrative
0 users have liked this narrative
WO
WVVI logo
woodworthfund on Willamette Valley Vineyards ·

Willamette Valley Vineyards (WVVI): Not-So-Great Value

Fair Value:US$247.5% overvalued
10 users have followed this narrative
0 users have commented on this narrative
1 users have liked this narrative

Updated Narratives

IN
PSD logo
IncomeAssets on Pulse Seismic ·

Watch Pulse Seismic Outperform with 13.6% Revenue Growth in the Coming Years

Fair Value:CA$4.4729.5% undervalued
3 users have followed this narrative
0 users have commented on this narrative
0 users have liked this narrative
VL
GGO logo
Vladislav on Galleon Gold ·

Significantly undervalued gold explorer in Timmins, finally getting traction

Fair Value:CA$482.8% undervalued
6 users have followed this narrative
0 users have commented on this narrative
0 users have liked this narrative
FU
CCP logo
FundamentallySarcastic on Credit Corp Group ·

Moderation and Stabilisation: HOLD: Fair Price based on a 4-year Cycle is $12.08

Fair Value:AU$12.6410.8% overvalued
6 users have followed this narrative
0 users have commented on this narrative
0 users have liked this narrative

Popular Narratives

TH
TheWallstreetKing
MVIS logo
TheWallstreetKing on MicroVision ·

MicroVision will explode future revenue by 380.37% with a vision towards success

Fair Value:US$6098.5% undervalued
116 users have followed this narrative
11 users have commented on this narrative
22 users have liked this narrative
AN
AnalystConsensusTarget
NVDA logo
AnalystConsensusTarget on NVIDIA ·

NVDA: Expanding AI Demand Will Drive Major Data Center Investments Through 2026

Fair Value:US$250.3926.8% undervalued
957 users have followed this narrative
6 users have commented on this narrative
25 users have liked this narrative
AN
AnalystConsensusTarget
GOOGL logo
AnalystConsensusTarget on Alphabet ·

GOOGL: AI Platform Expansion And Cloud Demand Will Support Durable Performance Amid Competitive Pressures

Fair Value:US$323.71.9% undervalued
1341 users have followed this narrative
0 users have commented on this narrative
17 users have liked this narrative

Trending Discussion